The Granston Memo’s Effect: The DOJ is Dismissing Meritless and Frivolous Actions
Posted on December 27, 2018 in Anti-Kickback Statute, FCA, Government Intervention, Pharmacy, Qui Tam
0
Tags: AbbVie, Bayer, dismiss, Eli Lilly, False Claims Act, FCA, Gilead, Granston, Health Choice, National Healthcare Analysis Group; NHCA